Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nintedanib Esylate

FDA-approved product (capsule, oral), marketed as Nintedanib Esylate, Ofev.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Nintedanib Esylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Idiopathic pulmonary fibrosis
  • Interstitial pneumonitis
  • Non-small cell lung carcinoma
  • Systemic scleroderma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nintedanib Esylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nintedanib Esylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)

    NCT07583589 · start 2026-05-12

    Registered record
    Registry ID
    NCT07583589
    Conditions
    Idiopathic Pulmonary Fibrosis (IPF)
    Interventions
    Nintedanib,Dextromethorphan; Nintedanib,Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-05-12
    Completion
    2027-06-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis (IPF)
    InterventionNintedanib,Dextromethorphan; Nintedanib,Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

    NCT07485920 · start 2026-05-01

    Registered record
    Registry ID
    NCT07485920
    Conditions
    Limited-stage Small Cell Lung Cancer (LS-SCLC)
    Interventions
    Tislelizumab and nintedanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-05-01
    Completion
    2030-01-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLimited-stage Small Cell Lung Cancer (LS-SCLC)
    InterventionTislelizumab and nintedanib
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants

    NCT07454291 · start 2026-04-28

    Registered record
    Registry ID
    NCT07454291
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    taladegib; nintedanib; pirfenidone; pirfenidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-04-28
    Completion
    2026-10
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    Interventiontaladegib; nintedanib; pirfenidone; pirfenidone
    PhasePhase 1
    Registry statusRecruiting

  • Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

    NCT07299695 · start 2026-01-25

    Registered record
    Registry ID
    NCT07299695
    Conditions
    Idiopathic Pulmonary Fibrosis; Acute Exacerbation of Idiopathic Pulmonary Fibrosis
    Interventions
    Intravenous immunoglobulin (IVIG); Usual treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-01-25
    Completion
    2028-12
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis; Acute Exacerbation of Idiopathic Pulmonary Fibrosis
    InterventionIntravenous immunoglobulin (IVIG); Usual treatment
    PhasePhase 3
    Registry statusRecruiting

  • Nintedanib for Improving Reproductive Outcomes in Adenomyosis

    NCT07162961 · start 2025-09-01

    Registered record
    Registry ID
    NCT07162961
    Conditions
    Adenomyosis of Uterus
    Interventions
    Nintedanib; Progesterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-09-01
    Completion
    2027-06-30
    Enrolment
    328

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenomyosis of Uterus
    InterventionNintedanib; Progesterone
    PhasePhase 3
    Registry statusNot yet recruiting

  • A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis

    NCT07080125 · start 2025-06-17

    Registered record
    Registry ID
    NCT07080125
    Conditions
    Interstitial Lung Diseases; Systemic Sclerosis Associated Interstitial Lung Disease
    Interventions
    Ofev®
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2025-06-17
    Completion
    2033-12-31
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInterstitial Lung Diseases; Systemic Sclerosis Associated Interstitial Lung Disease
    InterventionOfev®
    PhaseNot recorded
    Registry statusActive not recruiting

  • Nintedanib Treatment in Unicentric Castleman Disease

    NCT06643091 · start 2024-11-01

    Registered record
    Registry ID
    NCT06643091
    Conditions
    Castleman Disease
    Interventions
    Nintedanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-11-01
    Completion
    2030-09-01
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastleman Disease
    InterventionNintedanib
    PhasePhase 2
    Registry statusNot yet recruiting

  • Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC

    NCT06570317 · start 2024-08-24

    Registered record
    Registry ID
    NCT06570317
    Conditions
    NSCLC; Nintedanib; Radiation Pneumonitis
    Interventions
    Nintedanib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-08-24
    Completion
    2026-06-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC; Nintedanib; Radiation Pneumonitis
    InterventionNintedanib
    PhaseNot recorded
    Registry statusUnknown

  • A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers

    NCT06482190 · start 2024-07-11

    Registered record
    Registry ID
    NCT06482190
    Conditions
    Idiopathic Pulmonary Fibrosis; Lung; Disease, Interstitial, With Fibrosis
    Interventions
    RSN0402 Part 1; RSN0402 Part 2; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2024-07-11
    Completion
    2025-02-10
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis; Lung; Disease, Interstitial, With Fibrosis
    InterventionRSN0402 Part 1; RSN0402 Part 2; Placebo
    PhasePhase 1
    Registry statusUnknown

  • Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions

    NCT05635071 · start 2023-12-01

    Registered record
    Registry ID
    NCT05635071
    Conditions
    Uterine Adhesions
    Interventions
    Nintedanib 100 MG [Ofev]; Nintedanib 150 MG [Ofev]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2023-12-01
    Completion
    2024-12-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUterine Adhesions
    InterventionNintedanib 100 MG [Ofev]; Nintedanib 150 MG [Ofev]
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Faecal Microbiota Transplantation to Ameliorate Nintedanib-induced Diarrhea in Patients With Idiopathic Pulmonary Fibrosis

    NCT05755308 · start 2023-10

    Registered record
    Registry ID
    NCT05755308
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    Autologous FMT; Placebo FMT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-10
    Completion
    2026-04
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    InterventionAutologous FMT; Placebo FMT
    PhaseNot applicable
    Registry statusUnknown

  • Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

    NCT05195918 · start 2023-08-24

    Registered record
    Registry ID
    NCT05195918
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    EGCG 300 mg + Nintedanib; EGCG 300 mg + Pirfenidone; Placebo 2 capsules + Nintedanib or Pirfenidone; EGCG 600 mg + Nintedanib; EGCG 600 mg + Pirfenidone; Placebo 4 capsules + Nintedanib or Pirfenidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-08-24
    Completion
    2026-03-19
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    InterventionEGCG 300 mg + Nintedanib; EGCG 300 mg + Pirfenidone; Placebo 2 capsules + Nintedanib or Pirfenidone; EGCG 600 mg + Nintedanib +2 more
    PhasePhase 1
    Registry statusCompleted

  • Diarrheal Adverse Events in Caucasian Patients With Idiopathic Pulmonary Fibrosis Undergoing Treatment With Nintedanib

    NCT06714812 · start 2023-08-20

    Registered record
    Registry ID
    NCT06714812
    Conditions
    IPF
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2023-08-20
    Completion
    2025-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIPF
    InterventionNot recorded
    PhaseNot recorded
    Registry statusActive not recruiting

  • Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease

    NCT05335278 · start 2021-06-01

    Registered record
    Registry ID
    NCT05335278
    Conditions
    Interstitial Lung Disease; Myopathy, Inflammatory
    Interventions
    Nintedanib 150 milligrams [Ofev]
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2021-06-01
    Completion
    2025-04-30
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInterstitial Lung Disease; Myopathy, Inflammatory
    InterventionNintedanib 150 milligrams [Ofev]
    PhaseNot applicable
    Registry statusTerminated

  • INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

    NCT04702893 · start 2021-05-28

    Registered record
    Registry ID
    NCT04702893
    Conditions
    Lung Diseases, Interstitial
    Interventions
    Nintedanib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-05-28
    Completion
    2024-04-09
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Diseases, Interstitial
    InterventionNintedanib
    PhaseNot recorded
    Registry statusCompleted